In the course of recent years the accessibility of coagulation factor substitution treatment has significantly added to the improved consideration of individuals with hemophilia. Following the blood-borne viral diseases in the late 1970s and mid 1980, brought about by coagulation factor concentrates produced utilizing non-virally inactivated pooled plasma, the requirement for more secure treatment got pivotal to the hemophilia network. The presentation of infection inactivated plasma-determined coagulation factors and afterward of recombinant items has changed the consideration of these individuals. T
Research Article: Journal of Blood & Lymph
Research Article: Journal of Blood & Lymph
Research Article: Journal of Blood & Lymph
Research Article: Journal of Blood & Lymph
Case Report: Journal of Blood & Lymph
Case Report: Journal of Blood & Lymph
Case Report: Journal of Blood & Lymph
Case Report: Journal of Blood & Lymph
Review Article: Journal of Blood & Lymph
Review Article: Journal of Blood & Lymph
Posters & Accepted Abstracts: Alternative & Integrative Medicine
Posters & Accepted Abstracts: Alternative & Integrative Medicine
Posters & Accepted Abstracts: Alternative & Integrative Medicine
Posters & Accepted Abstracts: Alternative & Integrative Medicine
Keynote: Alternative & Integrative Medicine
Keynote: Alternative & Integrative Medicine
Accepted Abstracts: Alternative & Integrative Medicine
Accepted Abstracts: Alternative & Integrative Medicine
Posters & Accepted Abstracts: Journal of Physiotherapy & Physical Rehabilitation
Posters & Accepted Abstracts: Journal of Physiotherapy & Physical Rehabilitation
Journal of Blood & Lymph received 443 citations as per Google Scholar report